Fate Therapeutics (NASDAQ:FATE – Get Free Report) had its price objective cut by research analysts at BMO Capital Markets from $6.00 to $5.40 in a research note issued on Wednesday, Benzinga reports. The firm currently has a “market perform” rating on the biopharmaceutical company’s stock. BMO Capital Markets’ price target points to a potential upside […]
Fate Therapeutics, Inc to Post Q3 2023 Earnings of ($0 58) Per Share, HC Wainwright Forecasts (NASDAQ:FATE) etfdailynews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from etfdailynews.com Daily Mail and Mail on Sunday newspapers.
Fate Therapeutics (NASDAQ:FATE – Get Free Report) issued its quarterly earnings data on Tuesday. The biopharmaceutical company reported ($0.54) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.58) by $0.04, Briefing.com reports. The firm had revenue of $0.93 million during the quarter, compared to analysts’ expectations of $5.41 million. Fate Therapeutics […]
Fate Therapeutics (NASDAQ:FATE – Get Free Report) posted its earnings results on Tuesday. The biopharmaceutical company reported ($0.54) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.58) by $0.04, Briefing.com reports. Fate Therapeutics had a negative net margin of 171.64% and a negative return on equity of 45.62%. The firm had […]
Morgan Stanley Trims Fate Therapeutics (NASDAQ:FATE) Target Price to $5 00 kopsource.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from kopsource.com Daily Mail and Mail on Sunday newspapers.